FURTHER READING
American Diabetes Association. Implications of the diabetes control
and complications trial. Diabetes1993; 42 : 1555–8.
Bolli GB, Owens DR. Insulin glargine. Lancet2000; 356 : 443–5.
deFronzo RA, Goodman AM. Efficacy of metformin in patients with
non-insulin-dependent diabetes mellitus. New England Journal of
Medicine1995; 333 : 541–9 (see also accompanying editorial on met-
formin by OB Crofford, pp. 588–9).
Dornhorst A. Insulinotropic meglitinide analogues. Lancet2001; 358 :
1709–16.
Gale EAM. Lessons from the glitazones: a story of drug development.
Lancet2001; 357 : 1870–5.
Gerich JE. Oral hypoglycemic agents. New England Journal of Medicine
1989; 321 : 1231–45.
Hirsch IB. Drug therapy: Insulin analogues. New England Journal of
Medicine2005; 352 : 174–83.
Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet
2001; 358 : 739–46.
Perfetti R, D’Amico E. Rational drug design and PPAR agonists.
Current Diabetes Report2005; 5 : 340–5.
Pickup JC, Williams J (eds). Handbook of diabetes, 3rd edn. Oxford:
Blackwell Science, 2004.
Skyler JS, Cefalu WT, Kourides IA et al. Efficacy of inhaled human
insulin in type 1 diabetes mellitus: a randomized proof-of-concept
study. Lancet2001; 357 : 324–5.
Yki-Jarvinen H. Drug therapy: thiazolidinediones. New England
Journal of Medicine2004; 351 : 1106–18.DRUGSUSED TOTREATDIABETESMELLITUS 291